Journal of Research in Pharmacy Practice

Association between troponin I level and cardiovascular risk factors in asymptomatic hemodialysis patients

Document Type : Original Article

Authors

. Shahram Taheri 1
. Ali Asghar Pilehvarian 2
. Nafiseh Akbari 1
. Samane Musavi 2
. Afsoon Emami Naeini 1

1 Department of Internal Medicine, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Biology, Payame Noor University, Isfahan, Iran

Abstract
Objective: Patients on hemodialysis (HD) have a high risk for cardiovascular morbidity 
and mortality. Cardiac troponins are biomarkers for diagnosing acute myocardial 
injury or infarction. There is considerable controversy that exists in the frequency and 
significance of cardiac troponins in predicting cardiac injury and ischemia in HD patients.
Methods: In this cross‑sectional study, all HD patients more than 18‑year‑old, who 
were at least 3 months under HD, and had no sign and symptom of active cardiovascular 
disease (CVD), in two HD centers were enrolled. One hundred and one patients fulfilled 
the inclusion criteria. Blood sample for cardiac troponin I (cTnI) was drown before 
the initiation of HD session during their routine monthly blood testing from patients’ 
vascular access arterial line. cTnI levels were measured by a high‑sensitivity assay, 
VIDAS troponin I Ultra kit, and correlated with patients’ demographic, clinical, and 
laboratory results.
Findings: The patients’ different demographic and clinical characteristics had no 
statistically significant correlation with troponin levels except for marginal trend for past 
medical history of diabetes and hyperlipidemia with corresponding P values of 0.072 
and 0.055. Twenty‑six patients had cTnI level more than 0.01 µg/L and only two patients 
had cTnI level more than 0.11 µg/L. For laboratory results, only fasting blood sugar 
had statistically significant correlation with patients’ cTnI level(r = 0.357, P = 0.0001).
Conclusion: Frequency of significant elevation of cTnI level in our asymptomatic 
HD patients was very low and if such elevation is found in this population, it may be 
considered as a sign of active CVD.

Keywords

Cardiovascular disease
hemodialysis
troponin I
1. Su WS, Clase CM, Brimble KS, Margetts PJ, Wilkieson TJ, 
Gangji AS. Waist‑to‑hip ratio, cardiovascular outcomes, 
and death in peritoneal dialysis patients. Int J Nephrol 
2010;2010:831243.
2. Babuin L, Jaffe AS. Troponin: The biomarker of choice for the 
detection of cardiac injury. CMAJ 2005;173:1191‑202.
3. Buiten MS, de Bie MK, Rotmans JI, Dekker FW, van Buren M, 
Rabelink TJ, et al. Serum cardiac troponin‑I is superior to 
troponin‑T as a marker for left ventricular dysfunction in 
clinically stable patients with end‑stage renal disease. PLoS 
One 2015;10:e0134245.
4. Badero OJ, Salifu MO. Prediction of hemodynamically 
significant coronary artery disease using troponin I 
in hemodialysis patients presenting with chest pain: 
A case‑control study. Cardiology 2009;114:292‑7.
5. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial 
infarction redefined – A consensus document of The Joint 
European Society of Cardiology/American College of 
Cardiology Committee for the redefinition of myocardial 
infarction. J Am Coll Cardiol 2000;36:959‑69.
6. Hickman PE, Potter JM, Aroney C, Koerbin G, Southcott E, 
Wu AH, et al. Cardiac troponin may be released by ischemia 
alone, without necrosis. Clin Chim Acta 2010;411:318‑23.
7. Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin 
Pathol 2004;57:1025‑6.
8. Van Lente F, McErlean ES, DeLuca SA, Peacock WF, Rao JS, 
Nissen SE. Ability of troponins to predict adverse outcomes 
in patients with renal insufficiency and suspected acute 
coronary syndromes: A case‑matched study. JAm Coll Cardiol 
1999;33:471‑8.
9. Resic H, Ajanovic S, Kukavica N, Masnic F, Coric A. Plasma 
levels of brain natriuretic peptides and cardiac troponin in 
hemodialysis patients. Bosn J Basic Med Sci 2009;9:137‑41.
10. Ie EH, Klootwijk PJ, Weimar W, Zietse R. Significance of 
acute versus chronic troponin T elevation in dialysis patients. 
Nephron Clin Pract 2004;98:c87‑92.
11. Alivanis P, Giannikouris I, Kaligas G, ArvanitisA, Volanaki M, 
Vogiatzis P, et al. Influence of different dialysis membrane 
types on cardiac‑specific troponin T levels. PROCEEDINGS 
of the 6th BANTAO Congress. BANTAO J 2003;1:89‑90.
12. Iliou MC, Fumeron C, Benoit MO, Tuppin P, Courvoisier CL, Calonge VM, et al. Factors associated with increased serum 
levels of cardiac troponins T and I in chronic haemodialysis 
patients: Chronic haemodialysis and new cardiac markers 
evaluation (CHANCE) study. Nephrol Dial Transplant 
2001;16:1452‑8.
13. Gaze DC, Collinson PO. Cardiac troponin I but not cardiac 
troponin T adheres to polysulfone dialyser membranes 
in an in vitro haemodialysis model: Explanation for lower 
serum cTnI concentrations following dialysis. Open Heart 
2014;1:e000108.
14. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, 
Dvorak DL, et al. Acute myocardial infarction and renal 
dysfunction: A high‑risk combination. Ann Intern Med 
2002;137:563‑70.
15. Brouns R, De Deyn PP. Neurological complications in renal 
failure: A review. Clin Neurol Neurosurg 2004;107:1‑16.
16. Xanthos T, Ekmektzoglou KA, Papadimitriou L. Reviewing 
myocardial silent ischemia: Specific patient subgroups. Int J 
Cardiol 2008;124:139‑48.
17. Marchant B, Umachandran V, Stevenson R, Kopelman PG, 
Timmis AD. Silent myocardial ischemia: Role of subclinical 
neuropathy in patients with and without diabetes. J Am Coll 
Cardiol 1993;22:1433‑7.
18. Mohi‑ud‑din K, Bali HK, Banerjee S, Sakhuja V, Jha V. 
Silent myocardial ischemia and high‑grade ventricular 
arrhythmias in patients on maintenance hemodialysis. Ren 
Fail 2005;27:171‑5.
19. McLaurin MD, Apple FS, Falahati A, Murakami MM, 
Miller EA, Sharkey SW. Cardiac troponin I and creatine 
kinase‑MB mass to rule out myocardial injury in hospitalized 
patients with renal insufficiency. Am J Cardiol 1998;82:973‑5.
20. Hussein M, Mooij J, Roujouleh H, Al Shenawi O. Cardiac 
troponin‑I and its prognostic significance in a dialysis 
population. Hemodial Int 2004;8:332‑7.
21. Segre CA, Hueb W, Garcia RM, Rezende PC, Favarato D, 
Strunz CM, et al. Troponin in diabetic patients with and 
without chronic coronary artery disease. BMC Cardiovasc 
Disord 2015;15:72.
22. Lin‑Tan DT, Lin JL, Wang LH, Wang LM, Huang LM, 
Liu L, et al. Fasting glucose levels in predicting 1‑year 
all‑cause mortality in patients who do not have diabetes 
and are on maintenance hemodialysis. J Am Soc Nephrol 
2007;18:2385‑91.
23. Snit M, Dwornicki M, Zukowska‑Szczechowska E, 
Grzeszczak W. Impact of glycemic control on survival of 
diabetic patients on chronic regular hemodialysis: A 7‑year 
observational study. Diabetes Care 2007;30:189.
24. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, 
Tahara H, et al. Impact of glycemic control on survival of 
diabetic patients on chronic regular hemodialysis: A 7‑year 
observational study. Diabetes Care 2006;29:1496‑500.
25. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, 
Kopple JD, Kalantar‑Zadeh K. Association between serum 
lipids and survival in hemodialysis patients and impact of 
race. J Am Soc Nephrol 2007;18:293‑303.
26. Kalantar‑Zadeh K, Block G, Humphreys MH, Kopple JD. 
Reverse epidemiology of cardiovascular risk factors in 
maintenance dialysis patients. Kidney Int 2003;63:793‑808.
Journal of Research in Pharmacy Practice
Volume 5, Issue 2
Spring 2016
Pages 101-105

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us